Vanguard Value ETF

Most Recent

  • uploads///cash rich companies
    Company & Industry Overviews

    How Tax Reform Affected Abbott’s 4Q17 Performance

    In 4Q17, Abbott Laboratories (ABT) reported $828 million in net losses, which came in at $0.48 per share.

    By Sarah Collins
  • uploads///EPS ESTIMATES
    Earnings Report

    ZBH’s 4Q17 Earnings Results Meet Analysts’ Estimates

    Zimmer Biomet Holdings announced its 4Q17 and 2017 results on January 30. The company’s sales exceeded analysts’ estimates, while its adjusted earnings per share managed to meet estimates.

    By Sarah Collins
  • uploads///guidance
    Company & Industry Overviews

    A Look at Johnson & Johnson’s 2018 Guidance

    Johnson & Johnson (JNJ) provided 2018 guidance during the company’s earnings results release on January 23, 2018.

    By Sarah Collins
  • uploads///DIABETES
    Company & Industry Overviews

    Developments in J&J’s Medical Device Business Could Drive Growth

    In October 2017, Johnson & Johnson (JNJ) exited its insulin pump business, which was experiencing a decline in sales due to the intense competition in the insulin pump market.

    By Sarah Collins
  • uploads///NASH
    Company & Industry Overviews

    Which Gilead Sciences Portfolio Could Give a Long-Term Boost

    NASH is a chronic disease related to steatosis wherein fat accumulates in the liver and can lead to inflammation, progressive fibrosis, and cirrhosis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Xeljanz Sees Rapid Adoption in 2017

    Xeljanz demand trends In 3Q17, Pfizer’s (PFE) Xeljanz reported revenue of ~$348 million, marking YoY (year-over-year) growth of ~48.1%. The drug saw sales of $935 million in the first nine months of 2017, a 44.1% YoY rise. In 3Q17, the drug’s new rheumatology prescriptions rose significantly. In September 2017, Xeljanz accounted for 9.8% of new prescriptions for RA (rheumatoid arthritis) in […]

    By Margaret Patrick
  • uploads///Forteo
    Company & Industry Overviews

    How Eli Lilly’s Forteo and Jardiance Are Performing

    In 3Q17, Eli Lilly’s (LLY) Forteo generated revenues of $441.7 million, ~13% growth on a year-over-year (or YoY) basis and a 1% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads/// Smart beta
    Real Insights

    Can Smart Beta Go Wrong?

    The smart beta approach aims to benefit from market inefficiencies to deliver higher risk-adjusted returns and improve diversification.

    By VanEck
  • uploads///medical device segment performance
    Company & Industry Overviews

    How JNJ’s Medical Devices Business Restructuring Efforts Are Panning Out

    In 3Q17, Johnson & Johnson (JNJ) reported ~$19.7 billion in sales. The company’s Medical Devices business generated ~33.5% of the total sales.

    By Sarah Collins
  • uploads///knee market share
    Company & Industry Overviews

    ZBH’s Persona Partial Knee Launch Expands Knee Implant Portfolio

    On September 11, 2017, Zimmer Biomet Holdings (ZBH) announced the launch of its Persona Partial Knee System.

    By Sarah Collins
  • Jury Hasn’t Decided on ETFs’ Role in Stock Market Rise
    Real Insights

    Jury Hasn’t Decided on ETFs’ Role in Stock Market Rise

    Although ETF (VTV) ownership increased substantially during the last 20 years, it still isn’t high enough to meaningfully impact stock prices.

    By Peter Barnes
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics’ Reference Testing, Hospital Outreach Segment

    With services offered to about half of the total hospitals, Quest Diagnostics (DGX) has become a leading provider of reference testing services in the United States.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    UnitedHealth Group Witnessed Robust Customer Growth in 1Q17

    In 1Q17, UnitedHealth Group’s (UNH) UnitedHealthcare business witnessed a 2.5 million year-over-year increase in customers.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    OptumRx Continues to Boost UnitedHealth’s Pharmacy Care Services

    In its bid to control healthcare costs, UnitedHealth Group’s (UNH) OptumRx segment has been actively deploying data analytics across its Optum platform.

    By Margaret Patrick
  • uploads///careadvantage
    Company & Industry Overviews

    Inside the Latest Capability Advancement in Johnson & Johnson’s Orthopedics

    On January 9, JNJ’s Medical Device division announced its Orthopedic Episode of Care Approach, a data-driven program that will accelerate value-based care.

    By Sarah Collins
  • uploads///revenues
    Company & Industry Overviews

    Analyzing Zimmer Biomet Holdings’ Financial Guidance for 2016

    Zimmer Biomet revised its 2016 guidance after reporting its 3Q16 earnings. Its guidance for fiscal 2016 is estimated to be $7.63 billion–$7.65 billion.

    By Sarah Collins
  • uploads///Profit GDP
    Company & Industry Overviews

    What’s Fueling the Bull Run? Richard Bernstein Explains

    A bull run with legs In Richard Bernstein Advisors’ October Insights newsletter, after dismissing the belief that the Federal Reserve is to blame for stock price inflation (IWD) (VTV), Richard Bernstein moved on to explain the reason for the current bull run. Stating that “fundamentals have improved dramatically, and have been a major support to the […]

    By David Ashworth
  • uploads///bg pm
    Company & Industry Overviews

    Bunge Has Declared a Quarterly Dividend of $0.38 per Share

    Bunge (BG) has a market capitalization of $7.7 billion. BG rose by 0.56% to close at $50.0 per share as of March 1, 2016.

    By Gabriel Kane
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.